2162 — Keymed Biosciences Income Statement
0.000.00%
Last trade - 00:00
- HK$9.76bn
- HK$7.28bn
- CNY354.10m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 110 | 100 | 354 |
Cost of Revenue | |||||
Gross Profit | — | — | 93.1 | 97.5 | 317 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 162 | 805 | 3,991 | 386 | 688 |
Operating Profit | -162 | -805 | -3,881 | -285 | -334 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -168 | -819 | -3,893 | -304 | -356 |
Provision for Income Taxes | |||||
Net Income After Taxes | -168 | -819 | -3,893 | -304 | -358 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -168 | -819 | -3,887 | -308 | -359 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -168 | -819 | -3,887 | -308 | -359 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.618 | -3.02 | -24.1 | -1.18 | -1.37 |
Dividends per Share |